$pali

Palisade Bio's $PALI sees a surge in mentions and engagements, driven by positive clinical development news and insider buying. However, concerns about potential stock breakdowns and market speculation linger.

About $pali

Palisade Bio is a biotechnology company focused on developing treatments for inflammatory bowel disease (IBD).

Insights

• $pali mentions hit [---] which is 115% higher than it's daily average.

Engagements: [------] (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [------]
[--] Month: [-------] -78%
[--] Months: [---------] +467%
[--] Year: [---------] +109%
1-Year High: [-------] on 2025-10-06
1-Year Low: [--] on 2025-05-24

Engagements by network (24h): YouTube: [--] Reddit: [--] X: [------]

Mentions: [---] (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [--]
1-Year High: [-----] on 2025-10-06
1-Year Low: [--] on 2025-06-05

Mentions by network (24h): YouTube: [--] Reddit: [--] X: [---]

Creators: [---] (24h)

Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning $pali in the last [--] hours which is up 189% from [--] in the previous [--] hours Daily Average: [--]
1-Year High: [---] on 2025-10-06
1-Year Low: [--] on 2025-06-05

The most influential creators that mention $pali in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@DSAkdag	[--]	[------]	[--]	[---]
@raheelmohmmed1	[--]	[---]	[--]	[---]
@chaotropy	[--]	[---]	[--]	[---]
@Tradingfast44	[--]	[---]	[--]	[---]
@SeanValenc89161	[--]	[---]	[--]	[---]
@Lola_La_Fleur_	[--]	[--]	[--]	[---]
@rashidamir668	[--]	[---]	[--]	[---]

View More

Sentiment: 35%

Sentiment 24-Hour Time-Series Raw Data
Current Value: 35%
Daily Average: 81%
[--] Month: 29% -21%
[--] Months: 29% -71%
[--] Year: 29% -71%
1-Year High: 100% on 2025-02-19
1-Year Low: 22% on 2025-06-12

Most Supportive Themes:

• Clinical Development and IND Submission: (38%) Palisade Bio's PALI-2108 is progressing towards Phase [--] development for IBD, with a Phase [--] UC IND submission anticipated in early [----].
• Insider Buying and Retesting: (25%) Discussions highlight insider buying by a director and stock retesting, suggesting potential positive market signals.
• Abstract Publication: (13%) The release of a PK profile, safety, and summary abstract for PALI-2108 marks a significant milestone in the company's R&D efforts.

Most Critical Themes:

• Breakdown Concerns and Buyout Delays: (13%) Concerns exist regarding potential stock breakdowns and possible delays in buyouts for related entities, indicating a cautious outlook.
• General Stock Mentions and Speculation: (13%) Numerous posts mention $PALI alongside many other tickers, suggesting broad market speculation rather than focused interest.

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing